Table 1.
Baseline Characteristics of Study Population by HIV Status
| Variable | HIV+a | HIV−b | p-Value |
|---|---|---|---|
| Number of unique individuals | 466 | 100 | |
| Number of study visits | 466 | 192 | |
| % Age ≥50 years | 132 (28.3) | 66 (34.4) | .124 |
| % Race | |||
| White | 278 (59.7) | 115 (59.9) | <.001 |
| Black | 114 (24.5) | 66 (34.4) | |
| Other | 74 (15.9) | 11 (5.7) | |
| % BMI | |||
| Normal | 239 (51.3) | 89 (46.4) | <.001 |
| Overweight | 173 (37.1) | 52 (27.1) | |
| Obese | 54 (11.6) | 51 (26.6) | |
| % Hepatitis C infection | 38 (8.2) | 28 (14.6) | .013 |
| CD4+ T cell count, median (IQR), cells/mm3 | 531 (367, 717) | ||
| Years since HAART initiation, median (IQR) | 2.2 (1.7, 2.3) | ||
| Standardized 25(OH)D, median (IQR), ng/mL | 18.5 (12.7, 24.7) | 18.0 (12.8, 21.7) | |
| Standardized 1,25(OH)2D, median (IQR), pg/mL | 48.2 (39.2, 58.2) | 47.5 (39.6, 57.4) | |
a
Refers to post-HAART samples from HIV-infected men with suppressed viral load (≤400 copies/mL).
b
Refers to samples from HIV-uninfected men.
BMI, body mass index; HAART, highly active antiretroviral therapy; IQR, interquartile range; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.